BEST UNLIMITED TURBO LONG CERTIFICATE - GILEAD SCIENCES | Real-time Euronext Paris 05:29:07 2024-05-02 EDT | ||
| 3.98 EUR | +0.73% |
|
| 1 month | -50.06% | ||
| 3 months | -62.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 3.98 | +0.73% | 11 |
| 24-04-30 | 3.951 | -12.02% | 53 |
| 24-04-29 | 4.491 | +8.14% | 74 |
| 24-04-26 | 4.153 | +3.93% | 70 |
| 24-04-25 | 3.996 | -16.00% | 68 |
Real-time Euronext Paris
Last update May 02, 2024 at 05:29 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| GT83S | |
| ISIN | DE000SD3JMV0 |
| Date issued | 2021-02-03 |
| Strike | 57.56 $ |
| Maturity | Unlimited |
| Parity | 2 : 1 |
| Emission price | 6.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.09 € |
|---|---|
| Lowest since issue | 3.032 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.51
USD
Average target price
83.84
USD
Spread / Average Target
+27.98%
- Stock Market
- Certificates
- GT83S Certificat
